Xencor (XNCR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xencor (XNCR)

XNCR 14.37

+5.0%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: fitzdad55 who wrote (50)	10/30/2014 12:12:48 PM
From: scaram(o)uche	Read Replies (2) of 136

>> I wouldn't jump to the conclusion that Ph2a data for 5871 in RA is going to be unfavorable << Unfavorable, or negative? I don't expect negative results. Why would anyone expect negative results, given rituximab, and results with other CD20-targeted therapies, anti-CD22 and anti-IL-6? I just don't expect results which point to commercial viability. >> wouldn't surprise me if the endpoints are met << Wouldn't surprise me, either. Simply wouldn't surprise me if the share price drops on having met endpoints. >> what would be the road ahead in RA for this therapy << Whichever company adopted it, if any, would need to beat anti-IL-6 in patients highly refractory to an ever-increasing variety of T cell-targeted agents. Good luck with that. (Yay, Giants!)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next